drugset / Trial / NCT07456605
Study of the Safety and Usefulness of Liposomal Curcumin in Multiple Myeloma
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to test the safety of in investigational drug called Liposomal curcumin (LipoCurc) and to find the highest dose that can be given without causing very severe side effects. To do this participants are given LipoCurc and are watched very closely to see what side effects they have and to make sure the side effects are not severe. If the side effects are not severe, then new participants will be given a higher dose of LipoCurc. Participants joining this study later on will get higher doses of LipoCurc than participants who join earlier. This will continue until a dose is found that causes severe but temporary side effects. Doses higher than that will not be given.
Timeline
- Start
- 2026-02-27
- Primary completion
- 2028-03-02
- Completion
- 2028-03-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Curcumin | Small molecule | 350 mg/m2 | Intravenous |
| Subject | Curcumin | Small molecule | 400 mg/m2 | Intravenous |
| Subject | Curcumin | Small molecule | 450 mg/m2 | Intravenous |
| Subject | Curcumin | Small molecule | 500 mg/m2 | Intravenous |